ArticleScientific reports2019
MSC Transplantation Improves Lacrimal Gland Regeneration after Surgically Induced Dry Eye Disease in Mice.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Mechanistic Insights Into UC-MSC Therapy in a BAC-Induced Dry Eye Model: TSG-6-Dependent Inhibition of the Th17/CCL20-CCR6 Chemotactic Axis.Investigative ophthalmology & visual science · 2026Article
- Therapeutic Potential of Adipose-Derived Mesenchymal Stem Cells Transplantation into the Lacrimal Gland in Patients with Sjögren Syndrome.Korean journal of ophthalmology : KJO · 2026Article
- Evaluating the efficacy of stem cells in treating severe dry eye disease.World journal of stem cells · 2025Review
- Identification of glutamine as a potential therapeutic target in dry eye disease.Signal transduction and targeted therapy · 2025Article
- Biomedical Application of MSCs in Corneal Regeneration and Repair.International journal of molecular sciences · 2025Review
- Progress and Prospects in the Treatment of Lacrimal Gland Dysfunction Diseases: From Traditional Treatment Methods to Stem Cell and Organoid Therapies.Stem cells international · 2025Review
- Current Advances in Regenerative Strategies for Dry Eye Diseases: A Comprehensive Review.Bioengineering (Basel, Switzerland) · 2023Review
- Regulation of Axon Guidance by Slit2 and Netrin-1 Signaling in the Lacrimal Gland of Aqp5 Knockout Mice.Investigative ophthalmology & visual science · 2023Article
- Human Lacrimal Gland Derived Mesenchymal Stem Cells - Isolation, Propagation, and Characterization.Investigative ophthalmology & visual science · 2023Article
- Newer approaches to dry eye therapy: Nanotechnology, regenerative medicine, and tissue engineering.Indian journal of ophthalmology · 2023Review
- Role of FGF10/FGFR2b Signaling in Homeostasis and Regeneration of Adult Lacrimal Gland and Corneal Epithelium Proliferation.Investigative ophthalmology & visual science · 2023Article
- Histochemical Comparison of Human and Rat Lacrimal Glands: Implications for Bio-Engineering Studies.Translational vision science & technology · 2022Article
- Therapeutic Potential of Mesenchymal Stem Cells in the Treatment of Ocular Graft-Versus-Host Disease.International journal of molecular sciences · 2022Review
- [Beyond esthetics-Regenerative medicine for severe diseases of the adnexa oculi].Die Ophthalmologie · 2022Review
- Lacrimal Gland Microenvironment Changes After Obstruction of Lacrimal Gland Ducts.Investigative ophthalmology & visual science · 2022Article
- Dental follicle mesenchymal stem cells ameliorated glandular dysfunction in Sjögren's syndrome murine model.PloS one · 2022Article
- Experimental Models, Induction Protocols, and Measured Parameters in Dry Eye Disease: Focusing on Practical Implications for Experimental Research.International journal of molecular sciences · 2021Review
- Mesenchymal stromal cells for the treatment of ocular autoimmune diseases.Progress in retinal and eye research · 2021Review
- Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.International journal of molecular sciences · 2020Review
- Mesenchymal Stromal Cell-Based Therapy for Dry Eye: Current Status and Future Perspectives.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED) is a multifactorial disease characterized by a disrupted tear film homeostasis and inflammation leading to visual impairments and pain in patients. Aqueous-deficient dry eye (ADDE) causes the most severe progressions and depends mainly on the loss of functional lacrimal gland (LG) tissue. Despite a high prevalence, therapies remain palliative. Therefore, it is of great interest to develop new approaches to curatively treat ADDE. Mesenchymal stem/stromal cells (MSC) have been shown to induce tissue regeneration and cease inflammation. Moreover, an increasing amount of MSC was found in the regenerating LG of mice. Therefore, this study investigated the therapeutic effect of MSC transplantation on damaged LGs using duct ligation induced ADDE in mice. Due to the transplantation of sex-mismatched and eGFP-expressing MSC, MSC could be identified and detected until day 21. MSC transplantation significantly improved LG regeneration, as the amount of vital acinar structures was significantly increased above the intrinsic regeneration capacity of control. Additionally, MSC transplantation modulated the immune reaction as macrophage infiltration was delayed and TNFα expression decreased, accompanied by an increased IL-6 expression. Thus, the application of MSC appears to be a promising therapeutic approach to induce LG regeneration in patients suffering from severe DED/ADDE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.